Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
Vigil Neuroscience to Present in Upcoming June Investor Conferences
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
Displaying 11 - 20 of 25